Fig. 7: Cpd G protects from renal injury in the mouse model of Alport syndrome. | Nature Communications

Fig. 7: Cpd G protects from renal injury in the mouse model of Alport syndrome.

From: Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease

Fig. 7

a–f Treatment outcomes of 8-week-old 129-Col4a3 KO after receiving vehicle (V) or Cpd G (100 mg/Kg/day) for 28 days. A group of Col4a3+/+ littermates (C) is included to show the healthy phenotype. a Albumin to creatinine ratio in spot urine samples; b serum creatinine levels; c blood urea nitrogen (BUN) levels; d body weights; e mesangial expansion scores determined in a blinded manner by a pathologist in PAS-stained kidney sections; f representative pictures of PAS-stained kidney sections from each treatment group. a–e Data expressed as the median and range. Groups treated with vehicle or Cpd G were compared using a double-tailed Mann–Whitney test (n = 4, U = 0, P = 0.0286); g survival curve of Col4a3 KO mice that received vehicle or Cpd G (100 mg/Kg/day) for 4 weeks starting at the age of 6 weeks.

Back to article page